NCT03982238 is a Phase 4 clinical trial of Insulin in Type 2 Diabetes, sponsored by Majianhua.

Who is sponsoring NCT03982238?

NCT03982238 is sponsored by Majianhua.

What drugs are being tested in NCT03982238?

Interventions in NCT03982238: Insulin, Metformin, Dapagliflozin.

What condition does NCT03982238 study?

NCT03982238 studies Type 2 Diabetes.

Is NCT03982238 still recruiting?

NCT03982238 is currently completed. Last updated 3 April 2020.

Last reviewed 2020-04-03 · How we verify

NCT03982238

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients

Completed Phase 4 Last updated 3 April 2020

What this trial tests

Phase 4 trial testing Insulin in Type 2 Diabetes in 74 participants. Completed in 31 December 2019.

Timeline

15 June 2019

Primary endpoint
15 November 2019

31 December 2019

Quick facts

Lead sponsor	Majianhua
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	15 June 2019
Primary completion	15 November 2019
Estimated completion	31 December 2019
Sites	1 location across China

Drugs / interventions tested

Insulin (insulin) — full drug profile →
Metformin (metformin) — full drug profile →
Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Majianhua

Who can join

Adults 18 to 60, male only, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will assess the total testosterone and sex hormone-binding globulin levels in men with type 2 diabetes before and after continuous subcutaneous insulin infusion and hypoglycemic drugs treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin.
Hu Y, Ding B, Shen Y, Yan RN, et al · · 2021 · cited 28× · PMID 33536253 · DOI 10.2337/dc20-1558
Low Total Testosterone Levels in Men with Newly Diagnosed Early-Onset Type 2 Diabetes: A Cross-Sectional Study in China.
Hu Y, Yuan L, Bao YJ, Wang Y, et al · · 2023 · cited 2× · PMID 37181070 · DOI 10.1155/2023/2082940
Short-time intensive insulin therapy upregulates 3 beta- and 17 beta-hydroxysteroid dehydrogenase levels in men with newly diagnosed T2DM.
Hu Y, Wang Y, Cai TT, Liu L, et al · · 2022 · cited 1× · PMID 35928897 · DOI 10.3389/fendo.2022.894743

Verify or expand the search:

Other trials of Insulin

Trials testing the same drug.

NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
NCT07259564 — A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) · Phase 2 · not yet recruiting
NCT06762314 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Phase 2 · recruiting
NCT06781775 — GDM: Insulin with or Without Metformin? · Phase 4 · recruiting
NCT06391853 — Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study · NA · withdrawn

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Majianhua trials

Trials by the same sponsor.

NCT04424706 — The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis · unknown
NCT03983187 — Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy · NA · unknown
NCT03983200 — Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03982238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Majianhua
Last refreshed: 3 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing